← Back to Search

Topical Agent

Tapinarof Cream for Plaque Psoriasis in Pediatric Subjects

Phase 3
Research Sponsored by Dermavant Sciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline
A PGA score of ≥ 2 at screening and baseline
Must not have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upweek 4 and week 12
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Study Summary

This trial is testing a new cream to see if it helps kids with plaque psoriasis.

Eligible Conditions
  • Plaque Psoriasis

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 and week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Investigator-Assessed Local Tolerability Scale (LTS) Scores
Number of subjects with clinically significant laboratory test abnormalities
+2 more
Secondary outcome measures
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Detectable Time-Point (AUC0-t) of tapinarof cream, 1%.
Maximum Plasma Concentration (Cmax) of tapinarof cream, 1%.
Time to Maximum Plasma Concentration (tmax) of tapinarof cream, 1%.

Side effects data

From 2021 Phase 3 trial • 763 Patients • NCT04053387
Dermatitis contact
Study treatment Arm
Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
tapinarof cream, 1%
Completed Phase 3

Find a Location

Who is running the clinical trial?

Dermavant Sciences, Inc.Lead Sponsor
5 Previous Clinical Trials
1,102 Total Patients Enrolled
Diana VillalobosStudy DirectorDermavant Sciences, Inc.
4 Previous Clinical Trials
1,810 Total Patients Enrolled

Media Library

Tapinarof (Topical Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05172726 — Phase 3
Plaque Psoriasis Research Study Groups: Open Label
Plaque Psoriasis Clinical Trial 2023: Tapinarof Highlights & Side Effects. Trial Name: NCT05172726 — Phase 3
Tapinarof (Topical Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05172726 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any restrictions on where this clinical trial can be accessed?

"This study is looking for participants from 11 different locations, which are listed on the website. If you are considering participating, it might be helpful to choose a site that is close to your home to avoid extra travel."

Answered by AI

At what age does this trial cutoff for participants?

"According to the study's inclusion criteria, patients between the ages of 2 and 17 are eligible to participate. There are a total of 36 trials for people under 18 and 159 for people over 65."

Answered by AI

How many people are being selected to participate in this research?

"Yes, the information on clinicaltrials.gov says that this trial is currently searching for candidates. The study was originally posted on December 2nd, 2021 and was most recently edited on February 23rd, 2022. The trial is looking for 100 participants at 11 sites."

Answered by AI

Are the results of this study on tapinarof cream, 1% in line with previous research?

"5 clinical trials for tapinarof cream, 1% are currently active, with 4 of those being Phase 3 trials. Rogers, Arkansas is the location for many of the trials, but there are a total of 232 sites running trials for this cream."

Answered by AI

Are there any short or long-term risks associated with tapinarof cream, 1%?

"There is some evidence of efficacy and extensive safety data available, so our team at Power gave tapinarof cream, 1% a score of 3."

Answered by AI

Which types of people would be able to join this research project?

"The aim of this study is to enrol 100 individuals with psoriasis aged 2-17. To be eligible, patients must: be male or female, have had the disease for 3 months or more, have plaque psoriasis covering 3% or more of their body, have a PGA score of 2 or more, not be pregnant, and use birth controlith psoriasis aged 2-17. To be eligible, patients must: be male or female, have had the disease for 3 months or more, have plaque psoriasis covering 3% or more of their body, have a PGA score of 2 or more, not be pregnant, and use birth control if they are sexually active and of childbearing age."

Answered by AI

Are new participants still being welcomed into this research project?

"Correct, the listed clinical trial on clinicaltrials.gov is actively recruiting patients. The posting date was December 2nd, 2021 and the most recent update was on February 23rd, 2022. They are looking for 100 patients that can visit one of the 11 locations."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
~56 spots leftby May 2026